Mark V. Sherrid

Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.

KathleenW. Wyrwich, E. McErlean, K. Wolski, 2024, Journal of the American College of Cardiology.

Efficacy and Safety of aficamten in Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4.

I. Olivotto, R. Barriales-Villa, M. Fifer, 2024, Journal of cardiac failure.